Interview with CEO and Co-Founder of Neurocarrus, Dr. Paul Blum

Neurocarrus is a drug development biotech company headquartered in Lincoln, Nebraska. The company was founded by prominent research scientists in the field of protein engineering from the University of Nebraska. Neurocarrus’ first drug candidate (N-001) is a first-in-class, non-addictive therapeutics to fulfill the unmet need for a product that can safely and specifically disrupt peripheral sensory neurons. It was engineered for individuals experiencing pain as a result of tissue injury or inflammation as well as patients with acute pain, such as pain following surgery. N-001 is a leading technology in the fight against the opioid crisis, which claims the lives of tens of thousands of Americans each year. A safe, effective treatment for pain, which results in a disease burden of over $635 billion in the US alone, would have a major impact on human health through increased mobility and generally improved life quality. With N-001, Neurocarrus hopes to accomplish this without systemic side effects like nausea, dizziness, and addiction.